Newron Pharmaceuticals S.p.A. (NWRN.SW) Stock Overview
Explore Newron Pharmaceuticals S.p.A.’s financial performance, market position, analyst ratings, and future outlook.
Newron Pharmaceuticals S.p.A. (NWRN.SW)
Key Financials
Key Financials
Market Cap
266.3M
P/E Ratio
-20.20
EPS (TTM)
$0.68
ROE
2.78%
NWRN.SW Stock Analysis & Investment Overview (SIX)
Our AI-powered analysis of Newron Pharmaceuticals S.p.A. (SIX: NWRN.SW) gives investors deep insight into how the stock performs on the SIX exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Newron Pharmaceuticals S.p.A.'s SIX-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of NWRN.SW on the SIX shows an RSI of 59.12, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $19.74 for the SIX listing.
Key metrics behind Newron Pharmaceuticals S.p.A.'s SIX-traded stock include a P/E ratio of -20.20 and a market capitalization of 266.3M. Combined with our AI analysis, these give both institutional and retail investors a clear view of NWRN.SW on the SIX.